Needham reiterated coverage on SI-BONE with a new price target
$SIBN
Medical/Dental Instruments
Health Care
Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $19.00 from $27.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/27/2026 | $21.00 | Buy | TD Cowen |
| 8/6/2024 | $27.00 → $19.00 | Buy | Needham |
| 3/28/2024 | $25.00 | Overweight | Piper Sandler |
| 10/12/2022 | $20.00 | Buy | Jefferies |
| 4/7/2022 | $34.00 | Overweight | Cantor Fitzgerald |
| 3/1/2022 | $30.00 → $28.00 | Overweight | Morgan Stanley |
| 1/18/2022 | $43.00 → $36.00 | Buy | B of A Securities |
| 12/21/2021 | $35.00 → $30.00 | Buy | Truist Securities |
8-K - SI-BONE, Inc. (0001459839) (Filer)
10-Q - SI-BONE, Inc. (0001459839) (Filer)
8-K - SI-BONE, Inc. (0001459839) (Filer)
TD Cowen initiated coverage of SI-BONE with a rating of Buy and set a new price target of $21.00
Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $19.00 from $27.00 previously
Piper Sandler initiated coverage of SI-BONE with a rating of Overweight and set a new price target of $25.00
SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/4chyjb8g/. Live audio of the webcast will be available on the "Investors" section of the company’s website at: www.si-bone.com. The webca
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets disciplineTom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board MemberAppointments build the financial and governance foundation for ViCentra’s next phase, following the recent scale-up of commercial manufacturing UTRECHT, The Netherlands, July 14, 2026 (GLOBE NEWSWIRE) -- ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced the appointment of Ian Wells as Ch
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 16, 2026, at 5:40 a.m. Pacific Time/ 8:40 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/b4rPMsFmx6FA94q8B8jb82. Live audio of the webcast will be available on the "Investors" section of the company's webs
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/4chyjb8g/. Live audio of the webcast will be available on the "Investors" section of the company’s website at: www.si-bone.com. The webca
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 16, 2026, at 5:40 a.m. Pacific Time/ 8:40 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/b4rPMsFmx6FA94q8B8jb82. Live audio of the webcast will be available on the "Investors" section of the company's webs
First Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $52.6 million, representing growth of 11.2%U.S. revenue of $49.3 million, representing growth of 10.0%Gross margin of 79.8% Net loss of $4.3 million, representing an improvement of 33.8% Adjusted EBITDA of $2.5 million, representing an improvement of over 440%$144.7 million in cash and equivalents Recent Operational Highlights (any comparisons are to the prior year period) Over 1,650 active U.S. physicians, representing growth of 17% $2.2 million in trailing 12-month average revenue per territory, representing an increase of 11%Expanded international presence with the launch
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets disciplineTom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board MemberAppointments build the financial and governance foundation for ViCentra’s next phase, following the recent scale-up of commercial manufacturing UTRECHT, The Netherlands, July 14, 2026 (GLOBE NEWSWIRE) -- ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced the appointment of Ian Wells as Ch
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with
Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay's total board membership to seven. "We are pleased to welcome these two transformational business leaders as new independent directors on the Board," said David Brabazon, Chairman of the Mainstay Board of Directors. "Their deep experience will be invaluable to Mainstay as we grow our business and pursue our mission to serve patients with intractable chronic low back pain." "As our business evolves and we continue to focus on commercial growth, broadening the industry expertise on our Board will help
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)